|Page (1) of 1 - 12/06/17||email article||print page|
(December 06, 2017)
Leprosy is a chronic infection caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The global market for leprosy is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.
Considering all these factors the market for leprosy treatment is expected to reach $ 3.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Sample Report Available at https://www.marketresearchfuture.com/sample_request/3862 .
Key players of Global Leprosy treatment Market:
Key players profiled in the report are Glaxo Smithcline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others.`
- To provide a detailed analysis of the market structure along with estimated future growth forecast for the next six years about various segments and sub-segments of the global leprosy treatment market.
- To provide insights about factors affecting the market growth.
- To analyze the global leprosy treatment market based on various factors - Price Analysis, Supply Chain Analysis, Porters Five Force analysis etc.
- To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries - the Americas, Europe, Asia Pacific along with Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future growth prospects.
- To provide country level analysis of the market which includes segmentation by drug class, disease type and market channel.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market.
- To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments that are currently taking place in the global leprosy treatment markets.
Browse complete report at https://www.marketresearchfuture.com/reports/leprosy-treatment-market-3862 .
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.
The global leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the market has been segmented as private, contract and others.
Company Name: Market Research FutureContact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune -
Related Keywords:Australia,Europe,Health & Medicine,Pharmaceuticals & Biotech,U.S,
Related Sites: DMN Newswire , USDailyNews , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter